1. Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review
- Author
-
Jinxiong Xia, Yingmei Wen, Mengxia Xiao, Dafu Ye, Yanjun Gao, Dongling Tang, Xiuyun Zhang, Jinling Chen, Qingqing Li, and Yi Yao
- Subjects
advanced lung adenocarcinoma ,sintilimab ,immune-related adverse events ,immune myocarditis ,immune hepatitis ,immune pneumonia ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
In a variety of cancers, immune checkpoint inhibitors (ICIs) have demonstrated substantial survival advantages. Nevertheless, the widespread use of ICIs in the clinic has resulted in a growing interest in immune-related adverse events (irAEs) and their treatment methods. This paper reports a case in which a patient with three sequential severe irAEs was successfully treated. After undergoing two regimens of sintilimab in conjunction with chemotherapy for advanced lung cancer, the patient developed myocarditis combined with hepatitis. Subsequently, the patient developed pneumonia following remission from treatment. We also discuss the mechanism of irAEs, principles of treatment, and progress in the study of biomarkers for early prediction of irAEs by reviewing the literature.
- Published
- 2024
- Full Text
- View/download PDF